CCRx tops one million Part D enrollees

The therapy is the first and only oral direct acting antiviral approved by the FDA for HCV infection.

Marta Wosinska, PhD, and Joey Mattingly, PharmD, MBA, PhD, joined Drug Topics to help us understand how pharmaceutical tariffs could potentially impact the pharmacy industry.

Investigators find that patients with moderate weight loss or those who were weight resistant still had improvement in cardiometabolic health.

In this episode, Natalie DiPietro Mager, PharmD, PhD speaks with David Bright, PharmD, MBA, professor at Ferris State University College of Pharmacy.

This novel mechanism of action provides an alternative therapy for patients with recurrence or those who may not tolerate current first-line therapies.

Direct-to-consumer drug sales may undermine patient care and threaten independent pharmacies by reducing access to personalized, comprehensive medication management.